Biotech News
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen
Biogen Inc. and Stoke Therapeutics, Inc. have entered into a collaboration to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in all territories outside the U.S., Canada, and Mexico. The agreement grants Biogen exclusive commercialization rights outside these regions,
20 February 2025